LTF and neoplasm: In hepatocellular carcinoma (HCC), loss of ITLN1 correlates with aggressive clinicopathological features and poor outcomes, and restoration of omentin signaling—either directly or via lactoferrin-ITLN1 interactions—has demonstrated anti-tumor efficacy in preclinical models [49,50,51].